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ABSTRACT
Objective: To identify distinct behavioral phenotypes of behavioral-variant frontotemporal demen-
tia (bvFTD) and to elucidate differences in functional, neuroimaging, and progression to residen-
tial care placement.
Methods: Eighty-eight patients with bvFTD were included in a cluster analysis applying levels of
disinhibition and apathy (Cambridge Behavioural Inventory-Revised) to identify phenotypic sub-
groups. Between-group (Kruskal-Wallis, Mann-Whitney U) functional differences (Disability
Assessment for Dementia) and time to residential care placement (survival analyses) were exam-
ined. Cortical thickness differences (whole-brain MRI) were analyzed in patients with bvFTD vs
healthy controls (n 5 30) and between phenotypic subgroups.
Results: Four phenotypic subgroups were identified: primary severe apathy (n 5 26), severe
apathy and disinhibition (n 5 26), mild apathy and disinhibition (n 5 27), and primary severe
disinhibition (n5 9). Patients with severely apathetic phenotypes were more functionally impaired
and had more extensive brain atrophy than those with mild apathy or severe disinhibition alone.
Further imaging analyses indicated that the right middle temporal region is critical for the devel-
opment of disinhibition, an association that remains with disease progression and in the context
of severe apathy. Finally, no difference in time to residential care admission was found between
phenotypes.
Conclusions: This study reveals that different clinical behavioral phenotypes of bvFTD have dif-
fering profiles of functional decline and distinct patterns of associated cortical changes. These
findings emphasize the importance of apathy in functional impairment, highlight the role of the
right temporal region in disinhibition, and suggest that disability may be a sensitive outcome mea-
sure for treatments targeting reduction of apathy. These phenotypes could also support under-
standing of prognosis and clinical management. Neurology® 2017;89:1–8
GLOSSARY
ACE-III5 Addenbrooke’s Cognitive Examination-III; ACE-R5 Addenbrooke’s Cognitive Examination-Revised; ADL5 activity
of daily living; bvFTD 5 behavioral-variant frontotemporal dementia; CBI-R 5 Cambridge Behavioural Inventory-Revised;
CI5 confidence interval;DAD5Disability Assessment for Dementia;MA1D5mild apathy and disinhibition; PSA5 primary
severe apathy; PSD 5 primary severe disinhibition; ROI 5 region of interest; SA 1 D 5 severe apathy and disinhibition.
Behavioral symptoms are salient in behavioral-variant frontotemporal dementia (bvFTD), yet
considerable phenotypic variability exists within the diagnosis.1 Clinical studies have paid par-
ticular attention to the symptoms of apathy and disinhibition, which have been identified as
causing the greatest caregiver distress.2,3 bvFTD has been classified into apathetic (primary
symptoms of aspontaneity, inertia, and slowness) or disinhibited (more distractibility, over-
activity, and restlessness) behavioral presentations.4 Subsequent studies investigated associations
of these behavioral phenotypes with metabolic and neuroanatomic characteristics.2,3,5–10
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Cognitively, apathetic bvFTD phenotypes
have frequently been reported as more impaired
than disinhibited,7,11 but there is no consensus
at present.12 The functional implication of
behavioral phenotypes on activities of daily liv-
ing (ADLs) and prognosis has not been fully
understood. Relative preservation of instru-
mental ADLs across both phenotypes has been
reported,11 but instrumental ADLs have been
subsequently described as more impaired in
apathetic phenotypes.7,13 Indeed, increasing
apathy has been correlated with declining func-
tional ability in bvFTD.13,14
This study aimed to identify different
behavioral profiles within bvFTD in a data-
driven approach. We hypothesized that apa-
thy, but not disinhibition, would be a strong
contributor to functional disability; that severe
apathy would be associated with a greater
spread of cortical atrophy; and that severe apa-
thy would contribute to more rapid placement
to residential care.
METHODS Participants. Eighty-eight individuals diagnosed
with bvFTD consecutively recruited by FRONTIER, the Fronto-
temporal Dementia Research Group in Sydney (Australia), were
included in the study. These individuals were compared with 30
age-, sex-, and education-matched healthy controls. Patients were
assessed in clinic between November 2007 and June 2015. Patients
were included if they met current criteria for either possible or
probable bvFTD1 (diagnoses were based on a multidisciplinary
consensus, neurologist and neuropsychologist), had a reliable proxy
informant to report on their behavior and everyday routine, did not
have major depression or other neuropsychiatric disease, and did
not have physical limitations that could affect ADLs. Disease
duration was estimated at the time of diagnosis from the onset of
symptoms as described by the caregiver. Controls were recruited
from the Neuroscience Research Australia Volunteer database.
Healthy controls scored above 88 of 100 on the Addenbrooke’s
Cognitive Examination-III (ACE-III)15 and 0 on the Sum of Boxes
score of the Clinical Dementia Rating scale.16
Standard protocol approvals, registrations, and patient
consents. This study was approved by the human ethics commit-
tees of the University of New South Wales and the South Eastern
Sydney and Illawarra Area Health Service. Written consent was ob-
tained from each participant and/or the primary caregiver.
Instruments. Behavioral symptoms were assessed with the Cam-
bridge Behavioural Inventory-Revised (CBI-R),17 functional dis-
ability with the Disability Assessment for Dementia (DAD),18
and general cognition with the Addenbrooke’s Cognitive
Examination-Revised (ACE-R; used until February 2014)19 and the
ACE-III20 (used after 2014). Appendix e-1 at Neurology.org gives
full details of the assessments.
Data analyses. Demographic and clinical variables. To
explore the existence of clinical phenotypes within the bvFTD
patient group (marked apathy or marked disinhibition on the
basis of current literature), a hierarchical agglomerative cluster
analysis was conducted. We applied the average-linkage method
with squared euclidean distance using only the 2 behavioral
subscales (disinhibition and apathy from the CBI-R) to determine
the optimal number of clusters for the data.21 Analysis of the
change in distance between the cluster mergers on the dendrogram
generated from this analysis (figure e-1) suggested that 4 clusters
were an appropriate solution for this data.22 This 4-cluster solution
was validated with 2 consecutive 2-step clustering procedures using
euclidean distance, each with a different information criterion
(appendix e-1 gives details of the procedure). The 4 clusters were
then used in the next phase of analyses to compare the bvFTD
subgroups (clusters) in terms of their ADL functioning.
Demographic data across the 4 cluster groups were compared
with Kruskal-Wallis tests and x2 tests for sex comparisons.
Kruskal-Wallis tests were also used to explore differences across
clusters for each DAD area (total DAD, basic ADLs, instrumental
ADLs, initiation, planning, execution). Mann-Whitney U tests
were then conducted for post hoc analyses with the Benjamini-
Hochberg procedure used for false discovery rate control of mul-
tiple comparisons.23
Finally, to understand if belonging to different bvFTD sub-
group clusters would lead to more rapid placement to residential
care, a Kaplan-Meier survival analysis was conducted. Placement
to residential care (survival time) was defined as time from symp-
tom onset to placement into residential care. Censoring was used
for patients who were still living at home at the time of analysis or
who remained at home until their death. All statistical analyses
were performed with SPSS 21.0 (IBM, Armonk, NY).
Imaging data analyses. Whole-brain structural MRIs were
acquired and processed for bvFTD (n5 72) and healthy controls
(n 5 30) as described in appendix e-1. Four sets of vertex-by-
vertex analyses were performed with general linear models to
examine whole-brain differences in cortical thickness between the
bvFTD subgroups resulting from the cluster analysis and healthy
controls. Statistical significance was set at p 5 0.001 uncorrected
for multiple comparisons. Furthermore, direct comparisons
between bvFTD subgroups were carried out with t test analyses to
isolate the neural correlates of disease severity and disinhibition
associated with the different clinical phenotypes. Statistical sig-
nificance was set at p 5 0.01 uncorrected for multiple compar-
isons in these pairwise comparisons. A conservative cluster extent
threshold of k. 50 mm2 was used to minimize type I error while
balancing the risk of type II error.24
Next, 4 greater cortical regions of interest (ROIs), one for
each of the cortical lobes (frontal, temporal, parietal, and occipi-
tal), were selected, computed, and averaged across both hemi-
spheres (for details, see table e-1). One-way analysis of variance
was used to explore between-group differences in the average cor-
tical thickness within these ROIs. Post hoc analyses were cor-
rected for multiple comparisons with a Sidak adjustment.
Finally, regression analyses were used to test for significant linear
effects within these ROIs across the different groups. The level of
significance was set at p , 0.05.
RESULTS bvFTD phenotypes: Cluster demographics.
Clusters and healthy controls were matched for age,
sex distribution, and education (table 1). All cluster
groups were matched for disease duration; healthy
controls had better cognitive scores overall.
Are there distinct bvFTD phenotypes? Cluster solution
results. Figure 1 shows the 4 patient subgroups, which
were labeled to reflect clinical symptoms. Primary
severe apathy (PSA; n 5 26) was characterized by
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severe apathy scores and mild disinhibition scores;
severe apathy and disinhibition (SA 1 D; n 5 26)
was characterized by severe apathy and severe disin-
hibition scores; mild apathy and disinhibition (MA1
D; n 5 27) was characterized by mild apathy and
mild disinhibition; and primary severe disinhibition
(PSD; n 5 9) was characterized by mild apathy and
severe disinhibition. Group differences confirmed the
distinction of these 4 subgroups for both apathy
[x2(3) 5 64.641, p , 0.001] and disinhibition
[x2(3) 5 63.122, p , 0.001] CBI-R scores. Post hoc
tests revealed specific cluster group differences (figure 1).
Functional disability differences across bvFTD phenotypes.
Group differences were identified for every area of
daily function measured: overall ADLs [x2(3) 5
14.753, p , 0.005], basic ADLs [x2(3) 5 11.719,
p , 0.01], instrumental ADLs [x2(3) 5 13.236, p ,
0.005], and the 3 subcomponents of activity perfor-
mance: initiation [x2(3) 5 16.068, p , 0.005], plan-
ning [x2(3)5 9.957, p, 0.05], and execution [x2(3)5
10.391, p , 0.05]. Post hoc analyses compared
each cluster against the MA 1 D cluster (the least
impaired phenotype). Next, the PSA and PSD clus-
ters were compared. After multiple comparisons were
controlled for, the PSA and the SA 1 D subgroups
were more functionally impaired than the MA 1 D
group for every functional area. No differences
between the PSA and SA 1 D subgroups were found.
Clinically, this translates as people who had severe
Figure 1 Levels of apathy and disinhibition across patient subgroups (clusters) identified in 2-step cluster
analysis (with the Akaike criterion)
Higher scores indicate worse levels of behavioral expression. (A) PSA.MA1 D and PSD (bothU5 0.0, p, 0.001), SA1 D.
MA1 D (U5 0.50, p, 0.001) and PSD (U5 0.0, p, 0.001). (B) SA1 D. PSA andMA1 D (bothU5 0.0, p, 0.001), PSD.
PSA (U5 3.50, p, 0.001) and MA1D (U5 0.50, p, 0.001). CBI5Cambridge Behavioural Inventory-Revised; MA1D5
mild apathy and disinhibition; PSA 5 primary severe apathy; PSD 5 primary severe disinhibition; SA 1 D 5 severe apathy
and disinhibition. Mann-Whitney U tests (Bonferroni correction); *p , 0.001.
Table 1 Demographics for bvFTD behavioral phenotypes (cluster groups) and healthy controls
bvFTD all
(n 5 88)
PSA
(n 5 26)
SA 1 D
(n 5 26)
MA 1 D
(n 5 27)
PSD
(n 5 9)
Healthy
controls
(n 5 30)
Across clusters and
healthy controls
Across clusters
only
Statistic
x p
Statistic
x p
Age, y 62.15
(8.68)
63.96
(7.93)
60.00
(10.52)
62.30
(7.28)
62.67
(8.87)
64.53
(4.19)
5.30 0.258a 2.52 0.471a
Sex (M/F), n 54/34 15/11 16/10 17/10 6/3 12/18 4.42 0.353b 0.28 0.963b
Education, y 11.87
(2.96)
11.82
(3.31)
11.44
(2.58)
12.28
(3.00)
12.00
(3.16)
12.35
(1.22)
5.29 0.259a 0.81 0.846a
Disease duration, y 4.14
(2.42)
4.47
(2.40)
4.62
(2.63)
3.45
(2.37)
3.99
(1.82)
NA NA NA 4.31 0.230a
Baseline cognitive assessment;
maximum 100, cutoff 88/100
65.54
(14.83)
61.22
(14.07)
62.59
(18.25)
70.41
(9.74)
71.50
(15.00)
95.23
(3.58)
64.77 ,0.001a 6.88 0.076a
Abbreviations: bvFTD 5 behavioral-variant frontotemporal dementia; MA 1 D 5 mild apathy and disinhibition; NA 5 not applicable; PSA 5 primary severe
apathy; PSD 5 primary severe disinhibition; SA 1 D 5 severe apathy and disinhibition.
Scores are means (SDs). Disease duration refers to the time between symptom onset and baseline assessment date.
a Kruskal-Wallis test E.
bChi-square test.
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apathy were more disabled and had more difficulty
with their everyday living tasks than those with mild
apathy.
On the other hand, there were no differences
between the PSD and MA 1 D groups for any of
the functional domains, indicating that, in contrast to
those with a primarily apathetic presentation, patients
with a primarily disinhibited presentation may retain
some functional abilities. Surprisingly, there were no
differences between the PSA and the PSD groups.
Notably, the outlier included in the PSD group
(n 5 9) had a disease duration that was 5.26 years
longer than the average disease duration for that
group, had the equal highest concurrent levels of
apathy in the PSD group, and scored zero in overall
ADLs compared to the group mean of 60.57%
(figure 2).
Imaging analyses. Group comparisons between
bvFTD clusters and healthy controls revealed the
characteristic profile of brain atrophy consistent with
a diagnosis of bvFTD (figure e-2).8 In brief, all phe-
notypes (clusters) showed atrophy in the insula, infe-
rior frontal, and anterior temporal cortices with some
differences in the extent and location of the atrophy
between subgroups. Patients in the SA1 D and PSA
clusters (marked apathy) exhibited an extensive and
similar pattern of cortical thinning, with atrophy ex-
tending posteriorly to the temporoparietal junction
and regions of the posterior cingulate cortex and pre-
cuneus. Patients in the MA 1 D cluster showed
a similar pattern but with less extensive thinning. In
contrast, patients in the PSD cluster (marked disin-
hibition) showed focal atrophy in the bilateral orbito-
frontal, insular, and right anterior temporal and the
anterior cingulate cortex.
Pairwise comparisons between the SA 1 D and
PSA groups (both phenotypes, n 5 26) were carried
out to examine neural correlates of disinhibition, and
SA1D and MA1D were compared to examine the
neural correlates of apathy severity (figure 3). Disin-
hibition was associated with clusters of cortical thin-
ning in the left temporal pole and right inferior and
middle temporal gyri. Disease severity was associated
with clusters of thinning in the left inferior temporal
cortex and in the right insula, right middle temporal,
and parietal cortices and right posterior cingulate/
isthmus.
Finally, ROI analyses showed a linear trend
between symptom load/severity and cortical thinning
across the different clusters (from more to less severe
cortical atrophy: SA 1 D, PSA, MA 1 D, and PSD;
figure 4). These analyses yielded linear associations in
the frontal (R25 0.25, p, 0.0001), temporal (R25
0.19, p, 0.0001), parietal (R25 0.10, p5 0.0014),
and occipital (R25 0.10, p5 0.0014) lobes. Post hoc
comparisons of mean cortical thickness revealed dif-
ferences between patients from all clusters and
healthy controls in the frontal and temporal lobes
(both p , 0.001). In the parietal and occipital lobes,
differences were observed between patients from the
SA1D cluster and healthy controls (both p, 0.05).
No differences were observed between patient
subgroups.
Figure 2 Scatterplots showing scores for
functional domains for each cluster
phenotype
Low scores represent more impaired functional perfor-
mance. BADL 5 basic activities of daily living; DAD 5 Dis-
ability Assessment for Dementia; IADL 5 instrumental
activities of daily living; MA 1 D 5 mild apathy and disin-
hibition; PSA 5 primary severe apathy; PSD 5 primary
severe disinhibition; SA 1 D 5 severe apathy and disinhibi-
tion. Mann-Whitney U tests; *p , 0.007; **p , 0.005.
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bvFTD cluster phenotype and admission to residential
care. At the time of the study, 38 participants had
moved into residential care. One participant was
excluded from the analysis because symptom onset
information was unavailable. Therefore, 87 partici-
pants were included in the Kaplan-Meier survival
analysis to compare the 4 patient groups in regard to
admission to residential care. Overall, the median
time in years from diagnosis to residential care
admission for all the groups combined (n 5 87) was
2.8 years (95% confidence interval [CI] 2.3–3.2).
The median time from diagnosis to residential care
admission for each group ranged between 1.3 and 3.6
years (PSA: 1.3 years, 95% CI 0.0–3.8; SA 1 D: 3.0
years, 95% CI 1.4–4.5; MA1 D: 3.1 years, 95% CI
2.2–3.9; and PSD: 3.6 years, 95% CI 0.4–6.9), but
there were no differences between groups [figure e-3;
X(3) 5 0.511, p 5 0.916].
Figure 3 Patterns of brain atrophy derived from direct comparisons between different bvFTD phenotypes
Statistical significance was set at p 5 0.01 uncorrected for multiple comparisons. bvFTD 5 behavioral-variant frontotem-
poral dementia; MA 1 D 5 mild apathy and disinhibition; PSA 5 primary severe apathy; SA 1 D 5 severe apathy and
disinhibition.
Figure 4 Scatterplots of mean cortical thickness across the 4 cortical lobes
Mean cortical thickness was averaged for both hemispheres. HC 5 healthy controls; MA 1 D5mild apathy and disinhibition; PSA 5 primary severe apathy;
PSD 5 primary severe disinhibition; SA 1 D 5 severe apathy and disinhibition. *p , 0.05; **p , 0.001.
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DISCUSSION This study confirms the heterogeneity
of the bvFTD syndrome on the basis of severity of
apathy and disinhibited symptoms. Moreover, these
different bvFTD phenotypes have been translated
into distinct everyday living functional profiles and
are explained by different patterns of brain atrophy.
We confirmed our hypothesis that apathy, but not
disinhibition, had a greater negative effect on daily
functioning. Despite clear functional differences
between these behavioral phenotypes, they did not
appear to alter time to admission to residential care.
The recognition of different behavioral pheno-
types for bvFTD is consistent with previous stud-
ies.8,12 Consensus is lacking in regard to the number
of phenotypes; 2 (apathetic and disinhibited), 3
(included a mixed group), or, in the case of our study,
4 phenotypes have been reported. Similarly, 4 neuro-
anatomic bvFTD phenotypes have been identified in
2 separate studies; however, neither of these investi-
gated specific apathetic or disinhibited behavioral dif-
ferences.3,6 These variations are likely explained by
methodologic differences such as our data-driven
approach and use of different clinical assessment
tools. Other reasons for the divergence in findings
may include a different starting point in the analyses.
Previous studies set out from neuroanatomic pat-
terns,3,6 and some of the earlier studies predate the
current bvFTD diagnostic criteria and the delineation
of the C9ORF72 gene.1,25
The 4 behavioral phenotypes identified in our
study did not differ in terms of disease duration, sup-
porting the existence of distinct behavioral pheno-
types beyond what could be explained by behavioral
fluctuation across disease progression. Later in pro-
gression, however, the distinction becomes less clear,
with increasing levels of apathy overall and any ex-
pressions of severe disinhibition likely to decline.8,13
The outlier from the PSD group provides an example
of this: that patient had the longest disease duration
and highest levels of apathy in the group and was
much more functionally impaired.
Apathy appears to be more common than disinhi-
bition in bvFTD. Indeed, a greater proportion of pa-
tients with severe apathy were detected in our study,
reflecting previous findings.2,5 When present, disin-
hibition is generally accompanied by apathy.10,26 In
fact, the presence of severe disinhibition without apa-
thy was rare in our study. This profile may represent
a rare phenotype, which warrants further research
because it may have implications for clinical manage-
ment and prognosis. Disinhibition alone did not
seem to negatively influence functional impairment
in bvFTD, which contrasts with previous findings.14
This inconsistency is likely to be explained by the very
core definition of functional decline and selection of
clinical assessments.16,27
Confirmation that severe apathy results in greater
functional impairment has substantial clinical rele-
vance for 2 reasons: apathy is pervasive in bvFTD
and should be a primary focus of intervention,2 and
disinhibited behaviors (e.g., shoplifting or behaving
in a socially inappropriate manner) tend to dominate
the clinical picture to such an extent that apathy is
often overlooked. Therefore, pharmacologic and non-
pharmacologic interventions to improve ADL func-
tion (or to delay disease progression because these 2
domains overlap) should emphasize addressing task
initiation and planning deficits, which are commonly
associated with apathy.28 Introducing activities that
are intrinsically motivating and rewarding, broken
down to manageable elements and incorporated into
a patient’s routine, has been shown to be of some
benefit.29 Given the differences in functional impair-
ment across these phenotypes, future studies should
investigate the implications for caregiver burden.
There is potential that caregivers may benefit from
targeted approaches according to phenotype.
The 4 bvFTD phenotypes identified in our study
had clearly delineated behavioral and functional dif-
ferences. In contrast, no differences in general cogni-
tion were found, similar to a recent study.12 Overall,
other studies demonstrated that patients with a pre-
dominantly apathetic phenotype perform more
poorly on cognitive assessments than do those with
a disinhibited phenotype.7,11 Variation in cognitive
differences between studies may be down to the
choice of general cognitive assessment tools (e.g.,
Mini-Mental State Examination vs ACE-R) or diver-
gent methods of phenotypic separation (e.g., manual
classification vs cluster analysis).
Disinhibited behaviors have been associated with
higher levels of caregiver distress, and caregiver dis-
tress around neuropsychiatric symptoms can lead to
earlier residential care admission.30 While no differ-
ences between phenotypes regarding time to residen-
tial care admission were identified in our study,
information on the average time from diagnosis to
residential care admission for the bvFTD cohort as
a whole has clinical relevance. Our result indicating
admission to residential care 2.8 years after diagnosis
aligns with a recent German study that reported
a median of 2.0 6 2.5 years between diagnosis and
residential care admission for a bvFTD cohort.31
Future studies should investigate time from diagnosis
to residential care admission in a larger cohort of
bvFTD phenotypes.
The 4 behavioral phenotypes identified in the
cluster analysis were further supported by the imaging
analyses. Compared to healthy controls, patients with
the marked apathy phenotypes (PSA and SA 1 D)
had more extensive brain atrophy than those charac-
terized by mild apathy or marked disinhibition (MA
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1 D and PSD). The identified differences are in line
with recent studies that found that prefrontal and
temporal regions were differentially associated with
apathy and disinhibition in FTD.10,32 More specifi-
cally, the association with right middle temporal
region in the development of disinhibition also fits
with existing literature.10 This neuroanatomic delin-
eation aligned well with the clinical group differences,
which highlights that phenotypes with marked apathy
are more functionally impaired than phenotypes with
marked disinhibition. This, in turn, is strongly sup-
ported by our recent study that demonstrated the
critical role of apathy in longitudinal functional
decline in FTD.13
This study contains some limitations that need to
be considered in the interpretation of these results.
Foremost is the small size of the PSD subgroup,
which has implications for the different group com-
parisons and survival and imaging analyses. Because
of the small sample size of the PSD subgroup and
related limited statistical power, imaging analyses
were carried out uncorrected at a threshold of p ,
0.001 in comparisons with the control group and at
p , 0.01 in pairwise comparisons between bvFTD
phenotypes. This approach, however, yielded more
conservative maps of cortical differences than the
standard false discovery rate correction for multiple
comparisons in patients vs controls. Furthermore,
these analyses were constrained with a conservative
cluster extent threshold of k . 50 mm2 to balance
the risk of type I and type II errors.24 Finally, we did
not have pathologic confirmation of our bvFTD
cases. Future studies should address the differences
in pathology between these behavioral phenotypes
and investigate a larger cohort of the PSD phenotype.
In addition, the potential link between bvFTD phe-
notypes and time to residential care admission needs
to be further investigated.
The bvFTD phenotypic categories identified in
this study could support clinical decisions on prioriti-
zation of interventions to reduce disability and to pro-
vide information on prognosis for families. Further
potential for in vivo distinction of patients with dif-
fering pathologic processes could, in turn, help pre-
vent the dilution of positive effects in therapies that
occurs when patients are grouped under the single
umbrella of one overarching clinical syndrome.
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